These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

482 related items for PubMed ID: 31897953

  • 1. JAK inhibitors in refractory juvenile idiopathic arthritis-associated uveitis.
    Miserocchi E, Giuffrè C, Cornalba M, Pontikaki I, Cimaz R.
    Clin Rheumatol; 2020 Mar; 39(3):847-851. PubMed ID: 31897953
    [Abstract] [Full Text] [Related]

  • 2. Clinical effectiveness and safety of baricitinib for the treatment of juvenile idiopathic arthritis-associated uveitis or chronic anterior antinuclear antibody-positive uveitis: study protocol for an open-label, adalimumab active-controlled phase 3 clinical trial (JUVE-BRIGHT).
    Ramanan AV, Guly CM, Keller SY, Schlichting DE, de Bono S, Liao R, Quartier P.
    Trials; 2021 Oct 09; 22(1):689. PubMed ID: 34627340
    [Abstract] [Full Text] [Related]

  • 3. JAK inhibitors in the treatment of adult patients with juvenile idiopathic arthritis: a retrospective monocentric experience.
    Chighizola CB, Pellico MR, Pandolfi M, Marelli L, Cornalba M, Pontikaki I, Costi S, Gattinara M, Marino A, Miserocchi E, Caporali R.
    Clin Exp Rheumatol; 2024 May 09; 42(5):974-982. PubMed ID: 38530666
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Therapeutic potential of JAK inhibitors in juvenile idiopathic arthritis-associated uveitis.
    Maccora I, Land P, Miraldi Utz V, Angeles-Han ST.
    Expert Rev Clin Immunol; 2023 May 09; 19(7):689-692. PubMed ID: 37114341
    [No Abstract] [Full Text] [Related]

  • 6. Beneficial Effect of Upadacitinib in an Adult Patient with Juvenile Idiopathic Arthritis-associated Uveitis after Unsatisfactory Response to Tofacitinib: A Case Report.
    Baquet-Walscheid K, Heinz C, Rath T, Scheel M, Heiligenhaus A.
    Ocul Immunol Inflamm; 2023 Jul 09; 31(5):1079-1080. PubMed ID: 35587645
    [Abstract] [Full Text] [Related]

  • 7. Efficacy and safety of tofacitinib versus baricitinib in patients with rheumatoid arthritis in real clinical practice: analyses with propensity score-based inverse probability of treatment weighting.
    Miyazaki Y, Nakano K, Nakayamada S, Kubo S, Inoue Y, Fujino Y, Tanaka Y.
    Ann Rheum Dis; 2021 Sep 09; 80(9):1130-1136. PubMed ID: 33827788
    [Abstract] [Full Text] [Related]

  • 8. JAK inhibitors in refractory juvenile rheumatic diseases: Efficacy, tolerance and type-I interferon profiling, a single center retrospective study.
    Solignac M, Cabrera N, Fouillet-Desjonqueres M, Duquesne A, Laurent A, Foray AP, Viel S, Zekre F, Belot A.
    J Autoimmun; 2024 Jul 09; 147():103248. PubMed ID: 38797048
    [Abstract] [Full Text] [Related]

  • 9. A novel treatment for psoriatic arthritis: Janus kinase inhibitors.
    Chen M, Dai SM.
    Chin Med J (Engl); 2020 Apr 20; 133(8):959-967. PubMed ID: 32209886
    [Abstract] [Full Text] [Related]

  • 10. Treatment with Janus kinase inhibitors in juvenile dermatomyositis: A review of the literature.
    Sener S, Cam V, Ozen S, Batu ED.
    Semin Arthritis Rheum; 2024 Jun 20; 66():152426. PubMed ID: 38442462
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Effect of Janus Kinase Inhibitor Treatment on Anterior Uveitis and Associated Macular Edema in an Adult Patient with Juvenile Idiopathic Arthritis.
    Bauermann P, Heiligenhaus A, Heinz C.
    Ocul Immunol Inflamm; 2019 Jun 20; 27(8):1232-1234. PubMed ID: 31268748
    [Abstract] [Full Text] [Related]

  • 13. Tofacitinib in juvenile idiopathic arthritis: a double-blind, placebo-controlled, withdrawal phase 3 randomised trial.
    Ruperto N, Brunner HI, Synoverska O, Ting TV, Mendoza CA, Spindler A, Vyzhga Y, Marzan K, Grebenkina L, Tirosh I, Imundo L, Jerath R, Kingsbury DJ, Sozeri B, Vora SS, Prahalad S, Zholobova E, Butbul Aviel Y, Chasnyk V, Lerman M, Nanda K, Schmeling H, Tory H, Uziel Y, Viola DO, Posner HB, Kanik KS, Wouters A, Chang C, Zhang R, Lazariciu I, Hsu MA, Suehiro RM, Martini A, Lovell DJ, Paediatric Rheumatology International Trials Organisation (PRINTO) and Pediatric Rheumatology Collaborative Study Group (PRCSG).
    Lancet; 2021 Nov 27; 398(10315):1984-1996. PubMed ID: 34767764
    [Abstract] [Full Text] [Related]

  • 14. Adverse reactions to Janus kinase inhibitors: Study of their incidence and predictive factors in patients with rheumatoid arthritis.
    Martinez-Molina C, Guardiola Tey JM, Ruiz-Ramos J, Feliu A, Puig-Campmany M, Vidal S, Corominas H.
    Med Clin (Barc); 2024 Oct 25; 163(8):391-396. PubMed ID: 39003114
    [Abstract] [Full Text] [Related]

  • 15. [JAK Inhibitors in Rheumatology].
    Witte T.
    Dtsch Med Wochenschr; 2019 Jun 25; 144(11):748-752. PubMed ID: 31163474
    [Abstract] [Full Text] [Related]

  • 16. Use of tofacitinib in baricitinib-refractory atopic dermatitis: An example of JAK inhibitor switching.
    Dhir B, Meena SK, Sardana K, Sharath S.
    Pediatr Dermatol; 2024 Jun 25; 41(1):139-140. PubMed ID: 37495552
    [Abstract] [Full Text] [Related]

  • 17. Abatacept: a potential therapy in refractory cases of juvenile idiopathic arthritis-associated uveitis.
    Kenawy N, Cleary G, Mewar D, Beare N, Chandna A, Pearce I.
    Graefes Arch Clin Exp Ophthalmol; 2011 Feb 25; 249(2):297-300. PubMed ID: 20922440
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. JAK inhibitors are effective in a subset of patients with juvenile dermatomyositis: a monocentric retrospective study.
    Le Voyer T, Gitiaux C, Authier FJ, Bodemer C, Melki I, Quartier P, Aeschlimann F, Isapof A, Herbeuval JP, Bondet V, Charuel JL, Frémond ML, Duffy D, Rodero MP, Bader-Meunier B.
    Rheumatology (Oxford); 2021 Dec 01; 60(12):5801-5808. PubMed ID: 33576769
    [Abstract] [Full Text] [Related]

  • 20. Clinical significance of Janus Kinase inhibitor selectivity.
    Choy EH.
    Rheumatology (Oxford); 2019 Jun 01; 58(6):953-962. PubMed ID: 30508136
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 25.